Ingredients in every ml
|Ranitidine HCl||25 mg|
Each package contains
|ATC Level 1:||A - Alimentary tract and metabolism|
|ATC Level 2:||A02 - Drugs for Acid Related Disorders|
|ATC Level 3:||A02B - Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)|
18 YEARS OLD AND ABOVE
50 mg IM or IV 6-8 hourly.
Continuous IV infusion:
Dilute ranitidine 150 mg in 250 ml of 5% dextrose solution or other compatible IV solution and rate of infusion is 6.25 mg/hour for 24 hours.
For Zollinger-Ellison syndrome or other pathological hypersecretory conditions, ranitidine injection should be diluted to a concentration not greater than 2.5 mg/ml with 5% dextrose solution or other compatible IV solution. Initial infusion rate is 1 mg/kg body weight/hour and should be adjusted to patient's condition.
0 TO 18 YEARS OLD
Safety and efficacy in pediatrics has not been established
Active duodenal ulcer, pathological gastric ulcer, reflux esophagitis. Prevention of peptic ulcer relapse. Zollinger-Ellison syndrome.
All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.